|
|
|
|
Kyverna Therapeutics Inc (NASDAQ: KYTX) |
|
|
|
| |
KYTX's Free Cash Flow Growth by Quarter and Year
Kyverna Therapeutics Inc 's Free Cash Flow results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
Free Cash Flow Growth Y/Y▼
|
Free Cash Flow Growth Y/Y▼
|
| KYTX Free Cash Flow (in millions $) |
FY 2025 |
FY 2024 |
FY 2023 |
FY 2022 |
| 4th Quarter |
December |
-
|
-37.06
|
0.00
|
0.00
|
| 3rd Quarter |
September |
-
|
-27.49
|
0.00
|
0.00
|
| 2nd Quarter |
June |
-
|
-24.18
|
0.00
|
0.00
|
| 1st Quarter |
March |
-44.92
|
-25.53
|
0.00
|
0.00
|
| FY |
|
-44.92
|
-114.26
|
0.00
|
0.00
|
| KYTX Free Cash Flow first quarter 2025 Y/Y Growth Comment |
Kyverna Therapeutics Inc in the first quarter 2025 recorded free cash outflow of $ -44.92 millions.
According to the results reported in the first quarter 2025, Kyverna Therapeutics Inc achieved the best Free Cash Flow growth in Biotechnology & Pharmaceuticals industry. While Kyverna Therapeutics Inc ' s Free Cash Flow no change of 0% ranks overall at the positon no. in the first quarter 2025.
|
| KYTX Free Cash Flow ( Y/Y Growth %) |
2025
|
2024 |
2023 |
2022 |
| 4th Quarter |
December |
- |
- |
- |
- |
| 3rd Quarter |
September |
- |
- |
- |
- |
| 2nd Quarter |
June |
- |
- |
- |
- |
| 1st Quarter |
March |
- |
- |
- |
- |
| FY |
|
- |
- |
- |
- |
KYTX Free Cash Flow (Quarter on Quarter Growth %) |
2025
|
2024 |
2023 |
2022 |
| 4th Quarter |
December |
- |
- |
- |
- |
| 3rd Quarter |
September |
- |
- |
- |
- |
| 2nd Quarter |
June |
- |
- |
- |
- |
| 1st Quarter |
March |
- |
- |
- |
- |
| FY (Year on Year) |
|
- |
- |
- |
- |
| Free Cash Flow Y/Y Growth Statistics |
| High |
Average |
Low |
| 0 % |
0 % |
0 % |
|
|
|
|
|
| Free Cash Flow Y/Y Growth Statistics |
| High |
Average |
Low |
| 0 % |
0 % |
0 % |
|
|
|
|
| Free Cash Flow by Quarter for the Fiscal Years 2022, 2023, 2024, 2025 |
Kyverna Therapeutics Inc 's Q/Q Free Cash Flow Growth
| Free Cash Flow Q/Q Growth Statistics |
| High |
Average |
Low |
| 0 % |
0 % |
0 % |
|
|
|
| KYTX's I. Quarter Q/Q Free Cash Flow Comment |
I. Quarter 2025 free cash outflow of -44.92 millions by Kyverna Therapeutics Inc appear even less good compare to the -37.06 millions free cash outflow a quarter before.
Within Biotechnology & Pharmaceuticals industry Kyverna Therapeutics Inc achieved highest sequential Free Cash Flow growth. While Kyverna Therapeutics Inc 's Free Cash Flow growth quarter on quarter, overall rank is . |
|
|
|
| Free Cash Flow Q/Q Growth Statistics |
| High |
Average |
Low |
| 0 % |
0 % |
0 % |
|
|
|
| KYTX's I. Quarter Q/Q Free Cash Flow Comment |
Current accomplishment of -44.92 millions by Kyverna Therapeutics Inc look even more unfavourable considering the -37.06 millions free cash outflow a quarter before.
Within Biotechnology & Pharmaceuticals industry Kyverna Therapeutics Inc achieved highest sequential Free Cash Flow growth. While Kyverna Therapeutics Inc 's Free Cash Flow growth quarter on quarter, overall rank is . |
|
Kyverna Therapeutics Inc 's 12 Months Free Cash Flow Growth Year on Year
Free Cash Flow TTM Growth |
12 Months Ending
(Mar 31 2025) |
12 Months Ending
(Dec 31 2024) |
12 Months Ending
(Sep 30 2024) |
12 Months Ending
(Jun 30 2024) |
12 Months Ending
(Mar 31 2024) |
| Cumulative Free Cash Flow 12 Months Ending |
$ -133.64 |
$ -112.05 |
$ 0.00 |
$ 0.00 |
$ 0.00 |
| Y / Y Free Cash Flow Growth (TTM) |
- |
- |
- |
- |
- |
| Year on Year Free Cash Flow Growth Overall
Ranking |
# |
# |
# |
# |
# |
| Seqeuential Free Cash Flow Change (TTM) |
- |
- |
- |
- |
- |
| Seq. Free Cash Flow Growth (TTM) Overall
Ranking |
# |
# |
# |
# |
# |
| Cumulative Free Cash Flow growth Comment |
Kyverna Therapeutics Inc ' has realized cumulative trailing twelve months free cash outflow of $ -134 millions in the Mar 31 2025 period.
The situation is worsening as the cumulative free cash outflow is getting bigger from $ -112.05 millions for the period from Dec 31 2024 to Mar 31 2024 and $ millions from the TTM period ending Mar 31 2024.
Kyverna Therapeutics Inc achieved highest trailing twelve month year on year Free Cash Flow growth. While overall Free Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. . |
|
|
| Free Cash Flow TTM Y/Y Growth Statistics |
| High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
| Free Cash Flow TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# |
| Sector |
# |
| S&P 500 |
# |
|
| Cumulative Free Cash Flow growth
Comment |
Kyverna Therapeutics Inc ' has realized cumulative trailing twelve months free cash outflow of $ -134 millions in the Mar 31 2025 period.
The results are worsening as the cumulative free cash outflow is getting bigger from $ -112.05 millions for the period from Dec 31 2024 to Mar 31 2024 and $ millions from the TTM period ending Mar 31 2024.
Kyverna Therapeutics Inc achieved highest trailing twelve month year on year Free Cash Flow growth. While overall Free Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. . |
| Free Cash Flow TTM Y/Y Growth Statistics |
| High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
| Free Cash Flow TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# |
| Sector |
# |
| S&P 500 |
# |
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
119.14%